President of the Russian Federation Vladimir Putin took part in the launch of one of the country's largest production of active pharmaceutical substances at the production site of Promomed Group in Saransk
President of the Russian Federation Vladimir Putin took part in the launch of one of the country's largest production of active pharmaceutical substances at the production site of Promomed Group in Saransk
For more information
Promomed Group and the Department of Investment and Industrial Policy of the city of Moscow signed an agreement in the field of biotechnology development
Promomed Group and the Department of Investment and Industrial Policy of the city of Moscow signed an agreement in the field of biotechnology development
Today Promomed Group and the Moscow Department of Investment and Industrial Policy signed a cooperation agreement at the XXVI St. Petersburg International Economic Forum (SPIEF) in the interests of developing new high-tech sectors of the economy, creating new jobs in modern high-tech industries and in innovative companies.
For more information
Promomed launches the innovative import-substituting drug product Enligria for the treatment of overweight and obesity
Promomed launches the innovative import-substituting drug product Enligria for the treatment of overweight and obesity
Promomed Group, one of the leaders of the Russian pharmaceutical market, announced the launch of the first drug in Russia belonging to the glutide group (glucagon-like peptide receptor agonists) for the treatment of overweight and obese patients, as well as for the prevention of cardiovascular complications associated with these diseases.
For more information
PROMOMED obtained permission to produce drug product for diabetes mellitus Kvinsenta with semaglutide
PROMOMED obtained permission to produce drug product for diabetes mellitus Kvinsenta with semaglutide
The Russian government has published an order authorizing PROMOMED GROUP to use inventions protected by patents of the Danish company Novo Nordisk related to a drug product with semaglutide for the treatment of diabetes mellitus. PROMOMED has developed and produces Kvinsenta (semaglutide), used in the treatment of diabetes mellitus, including in patients with obesity and overweight or cardiovascular diseases.
For more information
Promomed Group is one of the leaders of the Russian pharmaceutical industry, an active participant in the national system for securing drug supply.
top-20
corporations by sales volume of domestic drugs on the pharmaceutical market in 2022
top-20
top-10
corporations by sales volume of domestic medicines in the public procurement market in 2022
top-10
82.4%
of drug products in the list of vital and essential medicines.
82.4%
>190
of certificates at the stage of development and registration of domestic drugs
300
drugs in the corporate portfolio of corporations by sales volume of domestic drugs in the pharmaceutical market
300
2 000+
qualified employees
Image block
The company implements a full cycle of pharmaceutical production: from molecule to finished dosage form.

Products

The portfolio of Promomed Group is based on original drugs developed in the large Research & Development Hub of the Group.
All products
Ambene Bio

Ambene Bio

Solution for intramuscular and intraarticular administrationA bioactive chondroprotector with a unique composition; produced using modern bioextraction process.
More details
Ambene Chondro

Ambene Chondro

CapsulesAmbene Chondro promotes suppression of the inflammatory response, normalizes metabolism in cartilage tissue and stimulates the production of synovial fluid in the joints.
More details
Areplivir

Areplivir

TabletsA targeted antiviral drug with a universal mechanism of action; suppresses various RNA viruses that cause a wide range of ARVIs, including COVID-19, influenza and many others. The effect of the drug does not depend on the type/strain of coronavirus.
More details
Brainmax

Brainmax

CapsulesBrainmax improves the function of brain cells, normalizes emotional state, eliminates chronic fatigue, increases the vital tone and performance of the body.
More details
Kombalgin Ice

Kombalgin Ice

Gel for topical useThe gel contains two active ingredients that provide a rapid analgesic and anti-inflammatory effect that lasts for 24 hours.
More details
Migrenium

Migrenium

Tablets A combination of active substances specifically developed to treat any kind of pain.
More details
Modelax-N

Modelax-N

Rectal solutionA laxative for adults and children, with a high safety profile that works at the right time, in a convenient place.
More details
Radamin Viro

Radamin Viro

solution for intramuscular and subcutaneous administrationRadamin Viro enhances cellular immunity, rapidly activates innate and acquired immunity.
More details
Reduxin Forte

Reduxin Forte

Tablets Reduxin Forte is a unique development of Promomed Group, which made expert level and healthy weight loss available to everyone.
More details
Reduxin

Reduxin

CapsuleReduxin is a faithful helper for overweight people on the path to forming a healthy lifestyle.
More details
Salvisar

Salvisar

OintmentViper venom based ointment for muscle, back and joint pain.
More details
Skyvira

Skyvira

Film-coated tablets.Skyvira helps to defeat the virus, prevents the development of complications and minimizes the post-COVID syndrome in patients with concomitant chronic diseases.
More details
Esperavir

Esperavir

CapsulesEsperavir is active against various RNA viruses: ARVI, influenza, SARS-CoV-2 and others.
More details
alt

Therapy areas

View all areas of activity
See more
View all areas of activity
See more

Production and innovations

The high quality of products of the Biokhimik plant of Promomed Group is guaranteed at all stages – from development to production of the finished dosage form and packaging.
Основной контент
79 mln pcs
vials of injectable antibiotics
79 <span>mln pcs</span>
825 mln pcs
tablets and capsules
825 <span>mln pcs</span>
15 mln tubes
ointments
15 <span>mln tubes</span>
173 mln pcs
finished pharmaceutical product
173 <span>mln pcs</span>
800,000 pcs
vials of lyopholysates
800,000 <span>pcs</span>
340 tons per year
AFS for 150 substances
340 <span>tons per year</span>
Production

Corporate Research Centre

The enterprise operates the largest Research & Development Hub a complex of research laboratories for the development of new drugs and finished dosage forms.

The center has all capabilities needed to:

quickly scale processes, which greatly accelerates the transfer of technologies to production and makes the adjustment stage and the stage of technical launch of a new drug product more efficient

Corporate Research Centre

Career

The main asset of PROMOMED Group is its employees.
One of our values, cooperation and development, reflects the culture and atmosphere in the company. We appreciate openness to new things, support those who want to learn, and we sincerely believe in what we do.
1500+
number of employees at Biokhimik JSC
1500+
20+
candidates of the medical, pharmaceutical and chemical sciences
20+
2000+
number of employees in the company
2000+

Pharmacovigilance

We carefully monitor the safety and effectiveness of all medicines that we manufacture or purchase for our customers.

Compliance control

As part of compliance control, we conduct regular audits of our processes and procedures to ensure that they comply with legislation and internal standards.